Clinical Trial

Activation of Autophagy and Suppression of Apoptosis by Dapagliflozin Attenuates Inflammatory Bowel Disease

Recruiting Phase 2/3
View on ClinicalTrials.gov →
Summary
The inflammatory bowel diseases (IBD) are described as complex, recurrent inflammatory conditions which are manifested as Crohn's disease (CD) and ulcerative colitis (UC). The common symptoms of IBD include debilitating/severe diarrhea, abdominal pain, weight loss, and chronic fatigue; events that may culminate in life-threatening complications. The pathogenesis of IBD has been characterized as complex/multi-factorial that includes disruption of intestinal epithelial barrier with consequent translocation of commensal microbial products as the prime event that instigates severe immune responses and intestinal inflammation.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2023-08-02; most recent amendment 2026-03-12.
Trial Details
NCT Number NCT05986136
Lead Sponsor Mostafa Bahaa
Conditions Inflammatory Bowel Diseases
Enrollment 50 participants
Start Date 2023-08-20
Primary Completion 2027-08-20 (estimated)
Study Completion 2028-07-20 (estimated)
Updated on ClinicalTrials.gov 2026-03-13